NexImmune Overview

  • Year Founded
  • 2011

Year Founded

  • Status
  • Out of Business

  • Employees
  • 72

Employees

  • Latest Deal Type
  • Liquidation

NexImmune General Information

Description

NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ the body's T cells to generate an antigen-specific cell-mediated immune response with curative potential for the patient. It creates therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. The company has two product candidates in human trials: NEXI-001 in acute myeloid leukemia, or AML, and NEXI-002 in multiple myeloma, or MM.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Corporate Office
  • 9119 Gaither Road
  • Gaithersburg, MD 20877
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • 9119 Gaither Road
  • Gaithersburg, MD 20877
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NexImmune Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
14. Bankruptcy: Liquidation 27-Aug-2024 Completed Bankruptcy: Liquidation
13. 2PO 05-Feb-2024 Completed Generating Revenue
12. IPO 12-Feb-2021 Completed Clinical Trials - Phase 1
11. Later Stage VC 31-Jan-2021 Completed Clinical Trials - Phase 1
10. Debt - PPP 30-Apr-2020 Completed Clinical Trials - Phase 1
9. Later Stage VC (Series A3) 27-Nov-2019 Completed Clinical Trials - Phase 1
8. Later Stage VC (Series A2) 22-Feb-2019 Completed Clinical Trials - Phase 1
7. Later Stage VC (Series A) 01-Jan-2018 Completed Clinical Trials - Phase 1
6. Buyout/LBO 14-Feb-2017 $5.25M Completed Clinical Trials - Phase 1
5. Early Stage VC 13-Feb-2015 $1.96M $5.25M Completed Clinical Trials - Phase 1
To view NexImmune’s complete valuation and funding history, request access »

NexImmune Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A-3
Series A-2
Series A 121,735,303 $0.000100 $0.02 $0.3 $0.3 1x $0.3 49.87%
To view NexImmune’s complete cap table history, request access »

NexImmune Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
NexImmune Inc is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to employ
Drug Discovery
Gaithersburg, MD
72 As of 2025

Cambridge, MA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

NexImmune Competitors (57)

One of NexImmune’s 57 competitors is Marengo Therapeutics, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Marengo Therapeutics Venture Capital-Backed Cambridge, MA
Iovance Biotherapeutics Corporation San Carlos, CA
Parvus Therapeutics Venture Capital-Backed South San Francisco, CA
Kite Pharma Formerly VC-backed Santa Monica, CA
Sorrento Therapeutics Formerly VC-backed San Diego, CA
You’re viewing 5 of 57 competitors. Get the full list »

NexImmune Patents

NexImmune Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2024206207-A1 Injectable artificial antigen presenting cells for immune therapy Inactive 24-Mar-2023
WO-2024148216-A2 Combination therapy with t cell engager Inactive 05-Jan-2023
WO-2024148216-A3 Combination therapy with t cell engager Inactive 05-Jan-2023
WO-2023288056-A2 Compositions and methods for expansion of hla-e-restricted t cell populations Inactive 15-Jul-2021
WO-2023288056-A3 Compositions and methods for expansion of hla-e-restricted t cell populations Inactive 15-Jul-2021 C07K14/70539
To view NexImmune’s complete patent history, request access »

NexImmune Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NexImmune ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Pharmaceuticals

Subindustry

Rank

Percentile

To view NexImmune’s complete esg history, request access »

NexImmune FAQs

  • When was NexImmune founded?

    NexImmune was founded in 2011.

  • Where is NexImmune headquartered?

    NexImmune is headquartered in Gaithersburg, MD.

  • What is the size of NexImmune?

    NexImmune has 72 total employees.

  • What industry is NexImmune in?

    NexImmune’s primary industry is Drug Discovery.

  • Is NexImmune a private or public company?

    NexImmune is a Private company.

  • What is NexImmune’s current revenue?

    The current revenue for NexImmune is .

  • How much funding has NexImmune raised over time?

    NexImmune has raised $185M.

  • Who are NexImmune’s competitors?

    Marengo Therapeutics, Iovance Biotherapeutics, Parvus Therapeutics, Kite Pharma, and Sorrento Therapeutics are some of the 57 competitors of NexImmune.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process